Niraparib oral capsule

DRUG2 trials

Sponsors

Sir Mortimer B. Davis - Jewish General Hospital, Institute of Cancer Research, United Kingdom

Conditions

Endometrial CancerOvarian Cancer RecurrentSerous AdenocarcinomaUterine Neoplasm

Early Phase 1

Niraparib in High-grade Endometrial Cancer Trial

WithdrawnNCT05289648

Sir Mortimer B. Davis - Jewish General HospitalEndometrial Cancer, Serous Adenocarcinoma, Uterine Neoplasm

Start: 2024-05-01End: 2026-01-31Updated: 2024-12-19

Phase 2

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

RecruitingNCT05990192

Institute of Cancer Research, United KingdomOvarian Cancer Recurrent

Start: 2024-06-20End: 2027-12-31Target: 42Updated: 2026-07-13